Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Registration Number
- NCT00035009
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression
- Detailed Description
The duration of treatment is 8 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 468
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in HAMD-17 total score at week 8. Mk-0869 will be generally well tolerated
- Secondary Outcome Measures
Name Time Method Actual CGI-I score at week 8, improving social disability by change from baseline in Sheehan Disability Score at Week 8, change from baseline in the HAMA score at week 8, change from baseline in depressed mood of the HAMD-17 at week 8